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1. Introduction 
Evolution of therapeutic monoclonal antibodies significantly benefited from the 
recombinant DNA technologies that are used to generate chimeric, humanized, and human 
versions of monoclonal antibody to reduce the problem of immunogenicity and 
neutralization, as well as from understanding mechanisms of action mediated by 
monoclonal antibodies (Nelson et al., 2010; Reichert, 2009; Ranson & Sliwkowski , 2002). 
One of the significant advances in the application of monoclonal antibodies in oncology was 
the introduction and approval of trastuzumab, a humanized anti-HER2 antibody, for the 
treatment of HER2-positive breast cancer. 
Despite initial successes and encouraging results, development of monoclonal antibody-based 
therapies faces several challenges (Yan et al., 2009). Among them are the selection of patients 
most likely to benefit from clinical trials and lack of understanding of mechanisms of 
resistance to monoclonal antibody-based therapies (Yan et al., 2009). Selection of patients most 
likely to benefit from clinical trials of monoclonal antibody-based therapies was initially based 
on the expression of the antigen targeted by the monoclonal antibody. The anti-HER-2 
antibody trastuzumab was tested in patients whose breast tumors overexpress HER2 (Pegram 
et al., 1998) and the anti-epidermal growth factor receptor (EGFR) antibody cetuximab was 
used in patients with colorectal cancer and head and neck cancers that overexpress EGFR 
(Shin et al., 2001). Even with careful characterization of the antigen expression level in the 
patient population eligible for the clinical trials, primary resistance to monoclonal antibody-
based therapies is a common problem. Up to 50% of EGFR-positive colorectal cancer patients 
are resistant to cetuximab (Saltz et al., 2004), and 74% of HER2-positive breast cancer patients 
are resistant to anti-HER2 antibody trastuzumab (Vogel et al., 2002). 
It has emerged that the levels of antigen expression are not the only determinant of the patient 
response to monoclonal antibody therapies and that better understanding of the mechanisms 
of resistance to monoclonal antibodies in different patient subgroups has a potential to 
improve the effectiveness of the monoclonal antibody treatment. A retrospective analysis of 
the colorectal tumor samples from the patients that received cetuximab therapy indicated that 
EGFR-positive colorectal cancer patients with wild-type KRAS gene had increased overall 
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survival, progression-free survival and improvement in the global health status compared to 
the patients whose tumors had KRAS mutations (Karapetis et al., 2008; Lievre et al., 2006). 
KRAS protein is a member of RAS super family of small GTP-binding proteins and a molecule 
downstream of the EGFR-mediated signaling cascade, and when aberrantly regulated, KRAS 
protein contributes to cancer development and progression (Karnoub & Weinberg, 2008). 
Cellular studies supported the role of KRAS mutations in the resistance to anti-EGFR antibody 
cetuximab (Benvenuti et al., 2007). Understanding of the role of the KRAS mutations in the 
resistance to the anti-EGFR antibody cetuximab has improved the selection of patients that are 
eligible for cetuximab treatment and as a consequence, cetuximab is currently approved for the 
treatment of EGFR-positive colorectal cancers that do not have KRAS mutations in codon 12 or 
13. While KRAS mutations play a critical role in diminishing response to cetuximab in 
colorectal cancer patients, KRAS gene is infrequently mutated in breast cancer (Karnoub & 
Weinberg, 2008; Sanchez-Munoz et al., 2010), and it is therefore not likely to contribute to the 
resistance to anti-HER2 monoclonal antibody trastuzumab. The molecular basis for the 
resistance to anti-HER2 monoclonal antibody trastuzumab in breast cancer is still not well 
understood, and there are no clinically useful predictive biomarkers that can be used in 
conjunction with HER2 expression to predict the outcome of trastuzumab treatment in the 
HER2-positive breast cancer patients. Breast cancer is one of the most common cancers among 
women in the United States. It is the second leading cause of cancer death in women, after 
lung cancer. Women with HER2-overexpressing breast cancers have an increased risk of 
recurrence and shortened disease-free and overall survival rates (Press et al., 1993; Slamon et 
al., 1987; Slamon et al., 1989). Understanding the mechanism of resistance to trastuzumab and 
identifying the predictive biomarkers for the therapeutic resistance to trastuzumab could lead 
to important therapeutic advances. 
Therapeutic monoclonal antibodies represent one of the most dynamic sectors in the 
biopharmaceutical industry (Reichert, 2009). Twelve monoclonal antibodies and antibodies-
related products are licensed for the diagnosis and treatment of specific oncology 
indications in the U.S. (Table 1) (Note: gemtuzumab ozogamicin was withdrawn from the 
market in June 2010). 
2. HER family of receptor tyrosine kinases 
HER2 is a member of the HER family of receptor tyrosine kinases, which is composed of 
four type I receptors: EGFR/HER1/ErbB1, HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4. 
All receptors share a similar structure composed of an extracellular ligand-binding region, a 
single transmembrane lipophilic segment and a cytoplasmic tyrosine kinase-containing 
domain (Zhang et al. 2007). The extracellular ligand-binding region of HER family receptors 
is composed of four domains (I-IV). Domains I and III are important for ligand binding. 
Domain II mediates receptor dimerization. Domain IV forms intramolecular interactions 
with the domain II and thus blocks dimerization (Garrett et al., 2003). Ligand binding to the 
extracellular domain of HER family members disrupts the autoinhibition conformation 
which results in the receptor homo- or hetero-dimerization, and transphosphorylation 
followed by the activation of the downstream signaling pathways which regulate cell 
growth and differentiation (Hudis, 2007; Hynes & Lane, 2005). The physiological ligand for 
HER2 has not been identified yet. HER3 function is particularly important due to its role in 
the development of resistance in HER2-overexpressing cancers. HER3 binds neuregulins via 
its extracellular region to mediate signals primarily by heterodimerization with HER2 in  
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Antibody 
name 
(USAN) 
Antibody 
tradename
Therapeutic 
target 
Antibody type Clinical Indication Year of 
approval 
Ipilimumab Yervoy CTLA-4 IgG1/human Advanced 
melanoma 
2011 
Ofatumumab Arzerra CD20 IgG1/human Chronic 
lymphocytic 
leukemia 
2009 
Panitumumab Vectibix EGFR IgG2/human Colorectal cancer 2006 
Cetuximab Erbitux EGFR IgG1/chimeric Colorectal cancer 
Head and Neck 
Squamous Cell 
Cancer  
2004 
 
2006 
Bevacizumab Avastin VEGF-A IgG1/humanized Colorectal cancer 2004 
 
I131-
Tositumomab 
Bexxar CD20 IgG2/mouse Non-Hodgkin 
lymphoma 
2003 
Y90 or I111-
Ibritumomab-
tiuxetan 
Zevelin CD20 IgG1/mouse Non-Hodgkin 
lymphoma 
2002 
Alemtuzumab Campath CD52 IgG1/humanized Chronic 
lymphocytic 
leukemia 
2001 
Gemtuzumab 
Ozogamicin 
Mylotarg CD33 IgG4/humanized 
linked to 
calichaemicin 
Acute myeloid 
leukemia 
2000 
withdrawn 
in June 
2010 
Trastuzumab Herceptin HER2 IgG1/humanized HER2-positive 
breast cancer 
1998 
Rituximab Rituxan CD20 IgG1/chimeric Non-Hodgkin 
lymphoma 
1997 
Capromab 
pendetide 
ProstaScint PSMA IgG1/murine Prostate cancer 
imaging 
1996 
Table 1. FDA approved monoclonal antibodies used for diagnosis and treatment of different 
oncological indications. 
tumors containing amplifications of HER2 (Baselga & Swain, 2009; Shi et al., 2010). In fact, 
HER3-HER2 is considered the most active HER signaling dimer (Tzahar et al., 1996). HER3 
also plays a key role in the ability of HER2-overexpressing cells to escape the growth 
inhibition by the EGFR/HER2 dual-specific tyrosine kinase inhibitor (TKI) lapatinib 
(Sergina et al., 2007). Previously, the intracellular kinase domain of HER3 was thought to be 
an inactive pseudokinase, because it lacks several key conserved and catalytically important 
residues (Guy et al., 1994, Sierke et al., 1997). Recently however, HER3 was shown to have 
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kinase activity and the ability to trans-autophosphorylate its intracellular region although it 
is substantially less active than EGFR (Shi et al., 2010). HER2 extracellular domain adopts a 
fixed conformation that resembles a ligand-activated state that permits it to form a dimer in 
the absence of a ligand (Cho at al., 2003; Garrett et al., 2003; Hynes & Lane, 2005). This likely 
explains why HER2 is the preferred dimerization partner for all of the other HER receptors 
(Graus-Porta et al., 1997). Moreover, although none of ligands for the HER family receptors 
directly binds to HER2, activation of EGFR, HER3, and HER4 can facilitate transactivation of 
HER2 through ligand-induced heterodimerization (Carraway et al., 1994; Wada et al., 1990).  
Overexpression of HER2 has been reported in different types of cancer, including breast, 
gastric, ovarian and salivary gland (Baselga & Swain, 2009). Gene amplification is the most 
common mechanism resulting in HER2 overexpression in tumors. In addition, somatic 
mutations in the HER2 tyrosine kinase domain are reported in lung adenocarcinomas, 
epithelial ovarian cancer, hepatocellular carcinoma, gastric, colorectal and breast cancers, 
but the activating function for these mutations has not been clarified (Bekaii-Saab et al., 
2006; Lee et al., 2006; Lin at al., 2011; Shigematsu et al., 2005). Recent studies also suggest 
that mutational inactivation in FOXP3 tumor suppressor may contribute to HER2 promoter 
activation in breast cancer tissues (Zuo et al., 2007). Regardless of the causative mechanisms 
resulting in HER2 overexpression in certain cancer, the number of HER2 molecules 
expressed on the surface of these cancer cells far exceeds the number expressed on normal 
cells, which facilitates the formation of HER2 heterodimers and the spontaneous formation 
of HER2 homodimers (Yarden & Sliwkowski, 2001). The consequence of this is an excess of 
HER2-mediated signaling, which drives oncogenic cell survival and proliferation (Yarden & 
Sliwkowski, 2001). 
3. Trastuzumab and mechanisms of action of trastuzumab 
For the past 20 years, the development of monoclonal antibodies and tyrosine kinase 
inhibitors (TKIs) targeting HER2 has been intensely pursued as important cancer 
therapeutic strategy. There are several reasons why HER2 is an attractive target in breast 
cancer treatment. First, the levels of HER2 in human cancer cells are higher than that in 
normal tissues and the elevated levels of HER2 correlate with the pathogenesis and 
prognosis in breast cancer (Natali et al., 1990; Slamon et al., 1987). Second, HER2 is 
overexpressed in approximately 20-30% of invasive breast cancer and is associated with 
poor disease-free survival and poor response to chemotherapy (Gusterson et al., 1992; Paik 
et al., 1990; Slamon et al., 1989). Third, HER2 is overexpressed in primary tumors and in 
metastatic sites suggesting that anti-HER2 therapy could be effective in all disease locations 
(Niehans et al., 1993). Trastuzumab is a recombinant humanized monoclonal antibody 
directed against the extracellular domain IV of HER2 and is approved for the treatment of 
HER2-positive breast cancer. In 2010, the European Medicines Agency approved 
trastuzumab for gastric cancer patients with high expression of HER2 (Okines et al., 2010). 
Subsequently, in October 2010, U.S. FDA approved trastuzumab in combination with 
chemotherapy for HER2-positive metastatic cancer of the stomach or the gastroesophageal 
junction.  
Trastuzumab was engineered by inserting the antigen binding loops of a murine antibody 
(clone 4D5) into the framework of a consensus human IgG1 using gene conversion 
mutagenesis strategy (Carter et al., 1992; Pegram et al., 1999). The humanized version of 4D5 
(also known as rhuMabHER2; later named trastuzumab) showed significant effects in 
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HER2-overexpressing breast cancer cells and in HER2-overexpressing xenograft breast 
cancer models either alone or in combination with other chemotherapy agents (Pegram et 
al., 1999). While the mechanisms by which trastuzumab induces regression of HER2-
positive breast cancers are still being investigated, it is currently believed that the binding of 
trastuzumab to HER2 contributes to its therapeutic effect by a) inducing HER2 endocytosis 
followed by receptor degradation; b) inhibiting either HER2 homodimerization or 
heterodimerization; c) preventing the cleavage of HER2 extracellular domain by the 
metalloprotease ADAM10 (Hudis, 2007). Taken together, binding of trastuzumab to the 
extracellular domain of HER2 reduces HER2-coupled mitogenic and pro-survival signaling 
pathways in tumor cells, leading to the inhibition of phosphatidylinositol 3-kinase (PI3K) 
and mitogen-activated protein kinase (MAPK) pathways, and the induction of the cyclin-
dependent kinase inhibitor, p27 (Nahta & Esteva, 2006). Furthermore, trastuzumab is an 
IgG1 subtype capable of inducing antibody-dependent cell mediated cytotoxicity (ADCC). 
Overexpression of HER2 in human tumor cells is closely associated with the increased 
angiogenesis and the expression of vascular endothelial growth factor (VEGF). Trastuzumab 
has also been shown to inhibit tumor angiogenesis, resulting in decreased microvessel 
density in vivo and reduced endothelial cell migration in vitro (Nahta & Esteva, 2006). 
4. HER2-overexpression and clinical indications for trastuzumab 
Trastuzumab is an anti-HER2 antibody indicated for the treatment of HER2-positive breast 
cancer and HER2-positive metastatic gastric or gastroesophageal (GE) junction 
adenocarcinoma. Three testing methodologies can be used to determine the HER2 status of 
the tumor samples: immunocytochemistry (IHC), fluorescence in situ hybridization (FISH), 
and chromogenic in situ hybridization (CISH) (Wolff et al., 2007). IHC detects the level of 
membrane bound HER2, whereas FISH and CISH detect the level of HER2 gene 
amplification. The American Society of Clinical Oncology/College of American Pathologists 
guideline was developed to define the status of HER2-positive breast cancer and 
recommended the use of a combination of IHC and FISH testing (Wolff et al., 2007). 
According to the guideline, a positive HER2 result is the IHC staining of 3+, and a FISH 
result of more than six HER2 gene copies per nucleus or a FISH ratio (HER2 gene signals to 
chromosome 17 signals) of more than 2.2 (Wolff et al., 2007). Trastuzumab was the first 
monoclonal antibody therapy to be approved with a companion diagnostic assay which was 
used to select the patients eligible for the trastuzumab treatment (Reichert, 2009).  
Trastuzumab, when used as a single agent, produced an objective response rate up to 26% in 
the selected HER2-positive metastatic breast cancer patients (Vogel et al., 2002). Preclinical 
studies of the combinations of trastuzumab and different chemotherapy agents suggested 
the potential for additive and/or synergistic effects in the clinical settings (Baselga et al., 
1998). Clinical studies then showed that trastuzumab in combination with chemotherapy in 
HER2-positive metastatic breast cancers significantly improved overall response rate, 
median overall survival, and time to disease progression (Burstein et al., 2001; Kaufman et 
al., 2009; Marty et al., 2005; O’Shaughnessy et al., 2004; Pegram et al., 1998; Perez et al., 2005; 
Slamon et al., 2001). Clinical benefit of trastuzumab treatment in HER2-positive metastatic 
breast cancer provided the rationale for testing the effects of trastuzumab treatment in the 
early stage HER2-positive breast cancer in the adjuvant and neoadjuvant setting. The 
adjuvant therapy is defined as any treatment given after the primary therapy, usually 
surgery, to increase the chance of long term survival, whereas neoadjuvant therapy refers to 
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the treatment given before the primary therapy. While many clinical trials are still ongoing, 
there are promising results for the use of trastuzumab treatment in the adjuvant and 
neoadjuvant settings. It was reported that one year of trastuzumab treatment after adjuvant 
chemotherapy significantly improved disease free survival and that trastuzumab combined 
concurrently with the chemotherapy improved the outcomes among HER2-positive breast 
cancer patients (Piccart-Gebhart et al., 2005). In addition to the use of trastuzumab in 
adjuvant settings, some of the clinical studies addressed the potential benefit of offering 
trastuzumab in the neoadjuvant settings. Results from the GeparQuattro study suggested 
that neoadjuvant combination of trastuzumab and different chemotherapy agents induced a 
high pathological complete response (pCR) rate with the minimal toxicities (Untch et al., 
2010). pCR is defined as the complete absence of intact tumor cells in the resected specimen. 
Trastuzumab is now a standard of care in combination with chemotherapy for patients with 
HER2-positive breast cancer (Banerjee & Smith, 2010).  
5. Resistance to the EGFR-targeted therapies 
Targeting the EGFR has been intensely pursued in the past decade as a cancer treatment 
strategy. Small molecule tyrosine kinase inhibitors (TKIs) and anti-EGFR monoclonal 
antibodies are the primary approaches to inhibit EGFR-coupled signaling pathways. To date, 
three tyrosine kinase inhibitors, erlotinib, gefitinib, and lapatinib, have been approved for 
oncology indications. Cetuximab, a chimeric IgG1 directed against the extracellular domain of 
EGFR, was originally generated from a murine antibody, 225 (Goldstein et al., 1995). 
Preclinical studies showed that cetuximab was more effective than the murine antibody 225 in 
inhibiting tumor growth in A431 human tumor xenografts model. Based on the preclinical 
studies, cetuximab was found to inhibit EGFR activation by preventing ligand binding, which 
inhibits EGFR dimerization and induces the EGFR internalization and downregulation 
(Goldstein et al., 1995; Mendelsohn, 2002). Cetuximab was approved in 2004 by FDA for the 
treatment of EGFR expressing metastatic colorectal cancer. In 2006, FDA approved the use of 
cetuximab for the treatment of locally advanced or regionally advanced head and neck 
squamous cell carcinomas (HNSCC). In 2006, panitumumab, a human antibody directed 
against the EGFR was also approved for the treatment of EGFR expressing metastatic 
colorectal cancer (Giusti et al., 2008; Hecht et al., 2009; Van Cutsem et al., 2007).  
Molecular mechanisms contributing to the resistance to EGFR kinase inhibitors have been 
extensively studied. Important findings suggest that there is a strong relationship between 
the resistance to EGFR TKIs and the absence of an activating mutation in the intracellular 
kinase domain of the receptor. These EGFR kinase domain mutations, such as the point 
mutation, L858R, and in-frame deletion in exon 19 around codons 746–750, enhance the 
ligand-dependent activation of EGFR, and simultaneously increase the sensitivity to the 
TKIs (Han et al., 2005; Mitsudomi et al., 2005; Morgillo et al., 2007). It has also been 
demonstrated that the patients with the EGFR mutation-positive tumors have an improved 
response rate and survival after treatment with TKIs compared to the patients with tumors 
that express wild-type EGFR (Han et al., 2005; Mitsudomi et al., 2005). Therefore, the lack of 
these mutations can be considered a predictor of the treatment resistance to TKI (Morgillo et 
al, 2007). Mechanisms contributing to the primary resistance to EGFR TKIs also include 
genetic alterations, for example, EGFR variant III (EGFRvIII) and activating KRAS 
mutations. EGFRvIII lacks the ligand binding domain and is a constitutively activated 
mutant. It has also been reported that a point mutation in the exon 20 (T790M) in the kinase 
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domain of the EGFR gene occurs in tumors with acquired resistance to EGFR kinase 
inhibitors, gefitinib and erlotinib (Pao et al., 2005). Because mutations within HER2 have not 
been commonly found in HER2-overexpressing breast tumors (Zito et al., 2008), the 
mechanisms of resistance to EGFR kinase inhibitors may not be relevant to trastuzumab. 
Although EGFR tyrosine kinase domain mutations may predict response to the TKIs, no 
mutations in the EGFR have been associated with resistance to the antibody-based therapies, 
cetuximab and panitumumab (Mukohara et al., 2005; Kruser & Wheeler, 2010). While EGFR 
gene amplification may be both predictive and prognostic and associated with the objective 
tumor response to cetuximab therapy, IHC based assay measuring EGFR expression may 
not be an accurate predictive factor for response to cetuximab therapy in colorectal cancer 
(Chung et al., 2005; Lievre et al., 2006), indicating that different mechanisms may contribute 
to cetuximab-resistance. One of the most reliable predictive biomarkers to emerge in the 
clinic has been that of the KRAS mutation status in colorectal cancer (Kruser & Wheeler, 
2010). Lievre et al. reported that KRAS mutation status was predictive of resistance to 
cetuximab therapy. In this report, 30 metastatic colorectal carcinoma patients treated with 
cetuximab were analyzed for KRAS mutations. The authors reported that KRAS mutation 
was found in 43% (13 tumors) and was significantly associated with resistance to cetuximab 
therapy (Lievre et al., 2006). A larger study was performed to measure the KRAS mutation 
status in 113 patients with refractory metastatic colorectal cancer treated with cetuximab. 
The authors found that KRAS wild-type is a strong predictor of significant increase in 
progression-free survival (PFS) and overall survival (OS) in this cohort of patients (De 
Roock et al., 2008). Many other clinical trials have confirmed these findings, leading to a 
Provisional Clinical Opinion from the American Society for Clinical Oncology (ASCO) 
stating that all patients with metastatic colorectal carcinoma who are candidates for anti-
EGFR antibody therapy should have their tumor tested for KRAS mutations in a Clinical 
Laboratory Improvement Amendments (CLIA)-accredited laboratory (Allegra et al., 2009). If 
codon 12 or 13 of KRAS is found to be mutated then patients with metastatic colorectal 
cancer should not receive anti-EGFR antibody therapy as a part of their treatment (Allegra et 
al., 2009).  
6. Therapeutic resistance to trastuzumab 
6.1 Clinical evidence for trastuzumab-resistance 
While trastuzumab has significantly changed the outcome for the treatment of HER2-
positive breast cancer, mechanisms contributing to trastuzumab-resistance are less well 
understood. Both primary and acquired resistance to trastuzumab pose a significant hurdle 
in the breast cancer therapy (Nahta & Esteva, 2006). Primary trastuzumab resistance refers 
to the lack of response to trastuzumab treatment in the patients with HER2-positive breast 
tumors who were never treated with trastuzumab before, whereas acquired resistance 
indicates that the patients who achieve initial response to trastuzumab acquire resistance to 
this antibody. In the study which evaluated the efficacy and the safety of trastuzumab as a 
single agent, the reported rate of primary trastuzumab-resistance was 74%, indicating that 
the vast majority of HER2-positive metastatic breast cancer patients demonstrate intrinsic 
resistance to single-agent trastuzumab (Vogel et al., 2002). Moreover, while addition of 
trastuzumab to chemotherapy in the cohort of HER2-positive metastatic breast cancer 
patients results in the higher response rates, and the extension of time to disease 
progression, the durations of response to trastuzumab in either the single-agent setting or in 
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the combination with chemotherapy has been reported to be 5-9 month (Kruser & Wheeler 
2010; Nahta & Esteva, 2006; Slamon et al., 2001). Therefore, the majority of patients with 
HER2-positive breast cancer develops acquired resistance within one year. (Kruser & 
Wheeler 2010; Nahta & Esteva, 2006; Slamon et al., 2001). Understanding the mechanisms of 
trastuzumab-resistance and developing predictive biomarkers for therapeutic resistance to 
trastuzumab are critical to the discovery of novel agents that could overcome trastuzumab-
resistance and potentially benefit HER2-positive breast cancer patients. 
6.2 Preclinical studies  
6.2.1 Cellular models used for the studies of trastuzumab-resistance 
There are several preclinical cellular models developed to study the mechanisms of 
resistance to trastuzumab. HER2-positive breast cancer cell lines were chronically exposed 
to trastuzumab either in vitro (SKBR3 cell line) or in xenograft settings (BT474 cell line) in 
order to develop trastuzumab-resistant clones and populations (Nahta et al., 2004a; Ritter et 
al., 2007). In this approach, a comparison between parental trastuzumab-sensitive and 
derived trastuzumab-resistant clones was carried out in order to characterize the changes in 
the cell signaling pathways associated with trastuzumab-resistance. Recently, the JIMT-1 cell 
line was established from a breast cancer patient with HER2 gene amplification and primary 
resistance to trastuzumab and was used to study the mechanisms of resistance to 
trastuzumab (Tanner et al., 2004). These trastuzumab-resistant cell lines still overexpress 
HER2, suggesting that resistance to trastuzumab is not due to the loss of HER2 
overexpression (Diermeier et al., 2005; Dokmanovic et al., 2009; Nagy et al., 2005; Ritter et 
al., 2007). Interestingly, it was reported recently that chronic exposure of BT-474 cells to 
trastuzumab gave rise to trastuzumab-resistant clones, which lost HER2 gene amplification 
and HER2 overexpression (Mittendorf et al., 2009). However, it is not clear whether 
trastuzumab eliminated HER2-overexpressing clones leaving only HER2-negative cancer 
clones or that the treatment with trastuzumab inhibited HER2 expression or induced 
downregulation of HER2, resulting in the loss of HER2 expression and resistance to 
trastuzumab.  
6.2.2 Molecular mechanisms of trastuzumab-resistance 
Trastuzumab-resistance may be broadly divided into two mechanistic categories. The first 
occurs at the cell membrane where aberrant regulation of HER2 results in deregulation of 
HER2 signaling pathways. The second results from changes to HER2-regulated intracellular 
signaling molecules that result in uncoupling signaling from their upstream regulation. 
Examples of the latter category include PTEN loss or expression of a constitutively activated 
PI3K mutant, PIK3CA.  
Based on in vitro breast cancer cell models of trastuzumab-resistance, HER2 interactions 
with other membrane-associated proteins contribute to resistance. For example, in the JIMT-
1 trastuzumab-resistant breast cancer cell line, binding of MUC4 glycoprotein to HER2 
partially masks the trastuzumab binding site in HER2, resulting in reduced trastuzumab 
binding and contributing to trastuzumab-resistance (Nagy et al., 2005). Trastuzumab 
binding to HER2 in JIMT-1 cells was restored by downregulation of MUC4 protein (Nagy et 
al., 2005). Formation of homodimers, and heterodimers between EGFR, HER2, and HER3 
due to overexpression of HER family ligands interferes with trastuzumab-mediated growth 
inhibition and contributes to trastuzumab-resistance (Diermeier et al., 2005; Motoyama 2002; 
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Ritter et al., 2007; Valabrega et al., 2005). In vitro models using breast cancer cells derived for 
resistance to trastuzumab found that Insulin-like growth factor-I receptor (IGF-IR) 
heterodimerizes with and phosphorylates ErbB2 suggesting that transactivation of ErbB2 by 
IGF1R may contribute to resistance (Nahta et al., 2005; Lu et al., 2004). Heterotrimerization 
of the growth factor receptors HER2, HER3 and IGF-IR in BT-474 breast cancer cells 
interferes with trastuzumab-associated p27 induction and therefore contributes to 
trastuzumab-resistance (Huang et al., 2010). Increased activity of small GTP-binding protein 
Rac1 interrupts with trastuzumab–induced HER2 endocytosis and degradation, resulting in 
the upregulated HER2-mediated signaling in SKBR3 breast cancer cells contributing to 
trastuzumab-resistance (Dokmanovic et al., 2009). The Met receptor tyrosine kinase, which 
is aberrantly expressed in breast cancer and predicts poor patient prognosis, is frequently 
expressed in HER2-overexpressing breast cancer cells, as well as in HER2-positive breast 
cancer, and Met activation protects cells against trastuzumab by abrogating p27 induction, 
thus contributing to trastuzumab resistance (Shattuck et al., 2008). Moreover, HER2-
overexpressing breast cancer cells rapidly up-regulate Met expression after trastuzumab 
treatment, promoting their own resistance (Shattuck et al., 2008). As mentioned in the 
previous paragraph, loss of HER2 expression in HER2-overexpression breast cancer cells 
could be another mechanism contributing to trastuzumab resistance (Mittendorf et al., 2009). 
HER2 receptor initiated downstream signaling promotes cell proliferation and cell survival 
by the activation of RAS-MAPK and PI3K/Akt/mTOR pathways (Hudis, 2007; Zhou et al., 
2004). Addition of trastuzumab to HER2-positive trastuzumab-sensitive cells results in the 
activation of PTEN, which acts as a tumor suppressor to induce inhibition of Akt 
phosphorylation and, therefore, antagonizes the PI3K/Akt survival pathway (Nagata et al., 
2004). Nagata et al. reported that reducing PTEN in breast cancer cells by antisense 
oligonucleotides conferred trastuzumab-resistance and that inhibition of PI3K activity 
enhanced trastuzumab–mediated growth inhibition in a trastuzumab-resistant xenograft 
model (Nagata et al., 2004). PTEN knockdown in a large scale of RNA interference screening 
was found to be associated with selective isolation of cell clones resistant to trastuzumab 
(Berns et al., 2007). Constitutive activation of PI3K, such as PIK3CA mutant, can uncouple 
Akt signaling from the upstream regulation resulting in trastuzumab-resistance (Berns et al., 
2007).  
6.3 Clinical studies  
Clinical studies have focused on characterization of the HER2 status and HER2-initiated 
downstream signaling pathways in the samples obtained from trastuzumab-sensitive 
patients and trastuzumab-resistant patients. A subtype of HER2-positive tumors with 
distinct biological and clinical features expresses a series of carboxyl terminal fragments of 
HER2 known as p95HER2. It is generally accepted that the p95HER2 can arise either by 
proteolytic shedding of the extracellular domain of the full-length HER2 by 
metalloproteinases ADAM10 at a site proximal to the transmembrane domain or by 
translation of the mRNA encoding truncated HER2 receptor from the internal initiation 
codons (Arribas et al., 2011). It is believed that trastuzumab has the ability to prevent 
proteolytic shedding of full-length HER2 on HER2-overexpressing breast cancer cells 
(Hudis, 2007). p95HER2 contains a hyperactive membrane anchored fragment that lacks the 
extracellular domain of HER2 and drives breast cancer progression in vivo. Of note, 
expression of p95HER2 fragments in transgenic mouse models leads to the generation of the 
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breast tumors that were more aggressive and metastatic than those driven by full-length 
HER2 (Pedersen et al., 2009). Expression of the p95HER2 fragment is predictive of poor 
prognosis and correlates with resistance to trastuzumab treatment in breast cancer patients 
(Arribas et al., 2011; Carney et al., 2003). This is likely due to the absence of the extracellular 
domain (ECD) required for trastuzumab binding (Arribas et al., 2011). The ECD of HER2 
can be released into the circulation after cleavage of HER2 by the metalloproteinases 
ADAM10. It was reported that the prevalence of increased levels of ECD in patient serum 
with primary breast cancer varied between 0% and 38%, whereas in metastatic breast cancer 
the range was from 23% to 80% (Carney et al., 2003). Moreover, Ali et al. reported that the 
decrease in serum levels of HER2 ECD was positively associated with trastuzumab-
sensitivity (Ali et al., 2008). In particular, in an analysis of 307 patients with metastatic breast 
cancer, individuals who did not achieve a significant decline (defined as ≥ 20%) in serum 
level of serum HER2 ECD after receiving trastuzumab had decreased benefit from 
trastuzumab-based therapy (Ali et al., 2008).  
The analysis of HER2 gene amplification before and after trastuzumab therapy suggested 
that patients who had lost HER2 gene amplification had a significantly decreased recurrence 
free survival (RFS) compared with patients whose tumors remained HER2 amplified after 
trastuzumab treatment (Mittendorf et al., 2009). Nagata et al. revealed that patients with 
PTEN-deficient breast cancers had significantly reduced responses to trastuzumab-based 
therapy than those with normal PTEN, suggesting PTEN deficiency may be a predictor to 
trastuzumab resistance (Nagata et al., 2004). Analysis of the 137 patient samples with HER2-
positive metastatic breast cancer who received trastuzumab therapy revealed that activation 
of PI3K either by PTEN loss and/or PIK3CA mutational activation was associated with a 
poor response to trastuzumab and a shorter patient survival time (Esteva et al., 2010). In a 
neoadjuvant clinical trial, which examined the association between response to trastuzumab 
therapy and the status of PTEN level and PIK3CA mutations, it was found that only 15.4% 
of subjects with low nuclear PTEN had pathological complete response (pCR) to 
trastuzumab compared to 44.4% of subjects with high nuclear PTEN levels. It was reported 
that 20% of patients with PIK3CA activating mutations achieved pCR compared to 38.1 % of 
patients with wild-type PIK3 status. When the two biomarkers (PTEN level and PIK3CA 
status) were combined together only 18.2% of patients with low PTEN or PIK3CA achieved 
pCR to trastuzumab compared to 66.7 % of patients who did not have low PTEN level or 
PI3KAC mutations (Dave et al., 2011). Taken together, loss of PTEN and PIK3CA activating 
mutations are associated with trastuzumab-resistance.  
Cyclin E is a critical regulator of the cell cycle G1/S transition and cyclin E levels are 
regulated by HER2 signaling in breast cancer cells (Mittendorf et al., 2010). Trastuzumab 
treatment reduces cyclin E level and activity in breast cancer cells (Mittendorf et al., 2010).  
It has been recently reported that in a cohort of 34 HER2-positive breast cancer patients 
treated with trastuzumab-based therapy, cyclin E amplification/overexpression was 
associated with a worse clinical benefit and a lower progression-free survival compared 
with non-overexpressing cyclin E tumors, suggesting that cyclin E amplification/ 
overexpression may contribute to trastuzumab-resistance in HER-positive breast cancer 
patients (Scaltriti et al., 2011). Interestingly, in an analysis of 26 tumor samples (10 cyclin E 
positive and 16 cyclin E negative), cyclin E amplification only partially correlated with other 
clinically relevant trastuzumab-resistant markers, such as p95HER2 and PTEN loss (Scaltriti 
et al., 2011). This suggests that cyclin E amplification/overexpression might use a different 
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mechanism to contribute to trastuzumab-resistance as compared to p95HER2 and PTEN 
loss. 
7. Toxicity and trastuzumab-related cardiotoxicity 
Trastuzumab is generally well tolerated with mild to moderate side effects and low 
incidence of chemotherapy associated adverse events (Brufsky, 2010). The side effects 
reported in different clinical trials include cardiomyopathy, infusion reactions, embryo-fetal 
toxicity, pulmonary toxicity, exacerbation of chemotherapy-induced neutropenia, diarrhea, 
burning sensation in the skin, rash, and nausea and vomiting, upper respiratory tract 
infection, increased cough. Among those side effects, the trastuzumab-related cardiotoxicity 
has drawn great attention for trastuzumab-based therapy.  
Trastuzumab associated cardiac dysfunction was initially reported in a phase III trial, which 
tested the efficacy of combining chemotherapy with trastuzumab versus chemotherapy 
alone in metastatic breast cancer disease (Slamon et al., 2001). The addition of trastuzumab 
increased the incidence of chemotherapy-associated symptomatic and asymptomatic cardiac 
dysfunction. These manifested as severe congestive heart failure and as significant decrease 
in left ventricular ejection function (LVEF) (Slamon et al., 2001; Sutter et al., 2007). In the 
subgroup that received anthracyclines, cyclophosphamide and trastuzumab, the incidence 
of cardiac dysfunction was 27% compared to 8% for the subgroup that received 
anthracyclines and cyclophosphamide alone (Slamon et al., 2001). For the subgroup that 
received paclitaxel and trastuzumab the incidence of cardiac dysfunction was 13% 
compared to 1% for the subgroup that received paclitaxel alone (Slamon et al., 2001). 
Although the results of trastuzumab adjuvant trials indicate that the incidence of 
trastuzumab discontinuation due to cardiac disorder was low (4.3%) and that most patients 
with cardiac dysfunction recovered within 6 months period (Sutter et al., 2007), the finding 
of trastuzumab-induced cardiac dysfunction has influenced the design of subsequent 
trastuzumab adjuvant trials and implementation of cardiac screening prior to and during 
the trastuzumab adjuvant trial (Sutter et al., 2007). Meta analysis of adjuvant trastuzumab 
clinical trials have assessed the incidence of cardiac dysfunction and found a favorable 
benefit to risk ratio for trastuzumab treatment in the early breast cancer (Viani et al., 2007).  
Cancer chemotherapy, in particular anthracycline therapy, was known to be associated with 
cardiac dysfunction, and trastuzumab treatment increased the incidence of chemotherapy-
induced cardiac dysfunction in the early trials with metastatic breast cancer patients 
(Slamon et al., 20001). Subsequent analysis indicated that trastuzumab-associated cardiac 
toxicity was clinically different than cardiac dysfunction associated with anthracyclines 
treatment (Ewer et al., 2005). Currently, trastuzumab-associated cardiac dysfunction is 
recognized as type II chemotherapy related cardiac dysfunction (Ewer & Lipmann, 2005). 
Clinical studies indicate that the increase in patient plasma troponin I levels, which has been 
proposed as an early marker of high dose chemotherapy (HDCT)-induced cardiac 
dysfunction, is associated with a risk of trastuzumab-induced cardiac dysfunction and the 
lack of left ventricular ejection fraction (LVEF) recovery (Cardinale et al., 2010). The 
evidence from the clinical trials indicate that trastuzumab-induced cardiomyopathy is not 
dose dependent, and that it is increased when trastuzumab is administered concurrently 
with anthracyclines, and that it is at least partially reversible (Ewer et al., 2005).  
HER2 signaling in heart is essential for cardiac development and function, as well as for the 
prevention of dilated cardiomyopathy (Negro et al., 2004). While the mechanisms 
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contributing to trastuzumab-induced cardiac toxicity are still incompletely understood, it 
appears that blocking HER2 with anti-HER2 antibodies increases the production of reactive 
oxygen species and reduces human cardiomyocyte cell viability (Gordon et al., 2009). In 
other studies, treatment of rat cardiomyocytes with anti-HER2 antibodies increased 
mitochondria-dependent apoptosis by modulating the levels of Bcl-XL and Bcl-xS (Grazette 
et al., 2004). Consistent with the above studies, HER2 knockout mice have ventricular 
trabeculation deterioration, dilated cardiomyopathy, and increased sensitivity to 
anthracyclines toxicity (Lee et al., 1995; Negro et al., 2004). Molecular mechanisms by which 
trastuzumab induces cardiac dysfunction still remain elusive.  
8. Strategies to overcome trastuzumab-resistance 
Most examples of acquired therapeutic resistance to receptor tyrosine kinase inhibitors 
(TKIs) include development of mutations within the targeted receptors. For example, 
mutations in BCR/ABL in chronic myeloid leukemia and c-kit in gastrointestinal stromal 
tumors confer resistance to a specific BCR/ABL, c-kit kinase inhibitor Imatinib (Gleevec) 
(Litzow, 2006). Improvement of the binding of small molecules to their targets has been 
successfully used as a strategy to overcome resistance to imatinib (Guilhot et al.,2007; le 
Coutre et al.,2008).  
While KRAS mutations have been found to be associated with primary resistance to 
cetuximab for the treatment of colorectal cancer, no predictive markers are currently used in 
the clinic to differentiate HER2-positive breast cancers that would respond favorably to 
trastuzumab from trastuzumab-resistant disease. Interestingly, KRAS, which signals 
downstream of both EGFR and HER2 receptors, is usually not mutated in HER2-positive 
breast cancer (Karnoub & Wenberg, 2008). Therefore, KRAS is not likely to contribute to 
therapeutic resistance to trastuzumab. Furthermore, mutations in HER2 have not been 
associated with resistance to trastuzumab. Based on these data, the strategies used to 
overcome therapeutic resistance to TKIs may not apply to trastuzumab-resistance. 
8.1 Small molecule inhibitors used for the treatment of trastuzumab-resistant disease 
Many new small molecule inhibitors are under clinical development to treat trastuzumab-
resistant breast cancers. Early clinical studies suggest that TKIs that specifically target 
EGFR and HER2 have anti-tumor effects. Lapatinib, a reversible inhibitor targeting the 
ATP binding site of the tyrosine kinase domain of EGFR and HER2, has a mechanism of 
action distinct from trastuzumab. Based on the evidence obtained from preclinical and 
clinical studies, lapatinib activity is not dependent on the PTEN, p95HER2, and PI3K 
mutation status (Bartsch et al., 2007; Nahta & Esteva, 2006). Preclinical studies indicate that 
lapatinib is effective in inducing apoptosis in trastuzumab-resistant HER2-overexpressing 
breast cancer cells (Konecny et al, 2006; Nahta et al., 2007). Results from a phase I study of 
lapatinib in a cohort of EGFR and/or HER2 overexpressing breast cancer patients indicate 
that lapatinib was well tolerated and produced partial responses in patients with 
trastuzumab-resistant breast cancer (Burris et al., 2005). Taken together, these studies 
provided the rationale for clinical studies to evaluate the effect of lapatinib plus 
trastuzumab on duration of response. A randomized study of lapatinib alone versus the 
combination of lapatinib and trastuzumab in patients with trastuzumab-resistant HER2-
positive metastatic breast cancer indicate that the combination of trastuzumab and 
lapatinib is superior to lapatinib alone for progression free survival (Blackwell et al., 2010). 
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Other TKIs in clinical development include neratinib which is a potent and irreversible TKI 
inhibitor of both EGFR and HER2. Neratinib showed promising results in clinical studies 
with HER2-positive breast cancer patients that were either heavily pretreated or not 
pretreated with trastuzumab (Burstein et al., 2010).  
HER2 activates the PI3K/Akt/mammalian target of rapamycin pathway (mTOR), which 
represents a central signaling pathway that promotes proliferation, invasion, and survival of 
breast cancer cells (Zhou et al., 2004). Activation of the PI3K pathway either by loss of PTEN 
or by an activating mutation in PI3K, PIK3CA, is associated with lower response to anti-
HER2 targeting agents, including trastuzumab (Berns et al., 2007; Nagata et al., 2004). 
Preclinical testing of combination of trastuzumab and PI3K, Akt or mTOR targeting agents 
showed that they have the potential to inhibit the growth of trastuzumab-resistant breast 
cancer cells and xenografts (Lu et al., 2007; Serra et al., 2008). These preclinical data are 
supported by recently published data of phase I trial where the oral mTOR inhibitor, 
everolimus, in combination with trastuzumab and vionorelbine had anti-tumor activity in 
HER2-positive metastatic breast cancer patients that progressed on trastuzumab (Jerusalem 
et al., 2011). Two additional mTOR inhibitors, rapamycin and temsirolimus, are also in 
clinical trials targeting trastuzumab-resistant breast cancers.  
The chaperon Hsp90 has been implicated in the stabilization of a number of cellular proteins 
that play central roles in signaling transduction processes (Pratt & Toft, 2003). It has been 
reported that the intracellular domain of HER2 binds to Hsp90 and binding of Hsp90 to 
HER2 not only serves to maintain its physiological conformation, but also to restrain HER2 
from forming active signaling dimer (Citri et al, 2004). Tanespimycin is a geldanamycin 
derivative that inhibits Hsp90 function in tumor cells, as well as in murine models (Zsebik et 
al., 2005). Cellular studies established that tanespimycin treatment either alone or in 
combination with trastuzumab inhibited cell growth and induced cell death in trastuzumab-
sensitive and in trastuzumab-resistant cell lines (Zsebik et al., 2005). The inhibition of cell 
growth by tanespimycin was associated with decrease in membrane bound HER2 levels, 
most likely due to ubiquitination and lysosomal pathway dependent HER2 protein 
degradation (Raja et al., 2008). A phase I clinical testing of a combination of trastuzumab 
and tanespimycin showed safe and active in trastuzumab-resistant breast cancer and 
induced antitumor activity in HER2-positive metastatic breast cancers (Modi et al., 2007). 
The following table provides information with regards to clinical trials testing multiple 
agents for the treatment of trastuzumab-resistant breast cancers. More detailed information 
can be found in the U.S. National Cancer Institute’s website at 
http://www.cancer.gov/clinicaltrials.  
8.2 Monoclonal antibodies indicated for the treatment of trastuzumab-resistant 
disease 
Pertuzumab is an IgG1 monoclonal antibody that binds to domain II of extracellular 
segment of HER2. Domain II mediates homo- and hetero-dimerization of HER2 with other 
members of the HER family. Therefore, binding of HER2 with pertuzumab prevents 
HER2-mediated dimerization and inhibits HER2-coupled signaling (Nahta et al., 2004b). 
Unlike pertuzumab, trastuzumab binds to domain IV of extracellular segment of HER2 
receptor (Franklin et al., 2004). Cellular studies indicate that the combination of these two 
anti-HER2 antibodies exhibited synergistic effects in inhibiting breast cancer cell survival 
(Nahta et al., 2004b).  
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Clinical trial combination therapy for 
trastuzumab-resistant HER2 positive 
breast cancer 
Molecular targets Phase of 
clinical study 
XL147/trastuzumab/paclitaxel PI3K/HER2/microtubules I,II 
BKM120/trastuzumab PI3K/HER2 I,II 
AUY922/trastuzumab Hsp90/HER2 I,II 
GRN163L/trastuzumab Telomerase/ErbB2 I 
Everolimus/trastuzumab/vinorelbine mTOR/HER2/tubulin III 
Rapamycin/trastuzumab mTOR/HER2 II 
Temsirolimus/neratinib mTOR/EGFR, HER2 I,II 
Panobinostat/trastuzumab Histone deacetylase 
(HDAC)/HER2 
I,II 
BIBW2992/vinorelbine EGFR, HER2/tubulin III 
BMS-754807/trastuzumab Insulin-like growth factor-I 
receptor, insulin receptor/HER2 
I,II 
Table 2. Ongoing clinical trials testing multiple agents for trastuzumab-resistant breast 
cancer. 
Addition of pertuzumab after progression to ongoing trastuzumab in xenografts 
synergistically increased tumor inhibition compared with trastuzumab alone (Friess et al., 
2005). Taken together, these data suggest that trastuzumab and pertuzumab have 
complementary mechanisms of action and that the addition of pertuzumab to trastuzumab 
may improve clinical efficacy as a result of potentially broader blockade of the HER tumor 
cell proliferation and survival signaling (Friess et al., 2005). A Phase II trial of combination 
of pertuzumab and trastuzumab in HER2-positive patients that progressed on trastuzumab 
therapy indicated that the combination was active and well tolerated and adverse events 
were mild to moderate (Baselga et al., 2010). Data from this Phase II clinical trial indicated 
that objective response rate was 24.2%, the clinical benefit rate was 50%, and progression-
free survival was 5.5 months in the cohort of patients (Baselga et al., 2010). Additionally, 
IMC-1121B (anti-VEGFR-2 monoclonal antibody) and IMC-18F1 (anti-VEGFR-1 monoclonal 
antibody) have been tested in clinical trials in combination with capecitabine, a 
chemotherapeutic agent that inhibits DNA synthesis and slows growth of tumor tissue, for 
the treatment of trastuzumab-resistant disease (National Cancer Institute, 2011; Schwartz et 
al., 2010; Spratin et al., 2010;).  
8.3 Optimization of antibody structures  
Advanced recombinant DNA technologies allow researchers to engineer therapeutic 
antibodies on a more rational basis. This can yield more homogeneous and stable molecules 
with additional properties such as increased cytotoxicity, dual-targeting, monovalent 
monoclonal antibodies, and enhanced penetration into solid tumors (Beck et al., 2010; Jin et 
al., 2008).  
The variable region (Fv) of a monoclonal antibody is responsible for the binding of antibody 
to the antigens. Affinity maturation technology has been used to improve the binding 
affinity and specificity of Fv to the target. Targeting c-Met with antibodies had been difficult 
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because most antibodies had intrinsic agonistic activity (Prat et al., 1998). A one-armed (OA) 
variant of the anti-c-Met antibody 5D5 was found to act as a pure antagonist and had the 
ability to inhibit the growth of cells dependent on SF/HGF-c-Met autocrine and paracrine 
signaling (Jin et al., 2008; Nguyen et al., 2003). Data have shown that monovalent 5D5 
antibody potently inhibited glioma growth in an orthotopic in vivo model (Martens et al., 
2006).  
The constant region (Fc) of an antibody is essential for the interaction between antibody and 
Fc receptors presenting on immune cells (Bruhns et al., 2009). Fc functions can be modulated 
by altering glycosylation status and binding affinity to Fc receptors, resulting in changes in 
antibody-dependent cellular cytotoxicity (ADCC), serum half-life, anti-inflammatory 
properties, and complement activation. Musolino et al. reported that the response to 
trastuzumab in metastatic breast cancer correlates with expression of the high affinity allele 
of the activating FcγRIIIa (CD16a)-158V/V (Musolino et al., 2008). It was recently reported 
that MGAH22, an anti-HER2 monoclonal antibody, was engineered in the Fc domain to 
increase binding to both alleles of the CD16a (Nordstrom et al., 2010). It was also reported 
that MGAH22 had enhanced activity against HER2-expressing tumors in hCD16a-158F 
transgenic mice (Nordstrom et al., 2010). A preclinical study showed that MGAH22 
conferred enhanced activity against HER2-positive breast tumor cells, including cells 
resistant to trastuzumab (Nordstrom et al., 2010). Furthermore, MGAH22 exhibited greater 
ADCC against HER2-expressing cancer cells with lower EC50 (Nordstrom et al., 2010). 
According to the information obtained from the website of the National Cancer Institute, 
MGAH22 is currently in phase I clinical trials for the treatment of the patients with the 
HER2-positive cancers, including breast cancer, that have not responded to the standard 
treatment (National Cancer Institute, 2011, http://www.cancer.gov/clinicaltrials).  
Multiple signaling pathways contribute to cancer development and progression. Bispecific 
antibodies, which are directed against two antigens that drive cancer progression, might 
yield better therapeutic efficacy than inhibition of a single target (Chames & Baty, 2009). 
Bispecific antibodies can be obtained by combining the variable domains of two already 
characterized monoclonal antibodies (two VL domains on the light chain and two VH 
domains on the heavy chain) using the dual variable domain IgG (DVD-IgG) technology.  
This technology enables the different specificities of two monoclonal antibodies to be 
engineered into a single functional, dual-specific, tetravalent IgG like molecule (Beck et al., 
2010). A different approach consists of engineering an additional paratope, the antigen-
binding site of an antibody, in the variable domain of an existing antibody, which results in 
simultaneous binding to two different antigens (Beck et al., 2010; Bostrom et al., 2009). The 
bispecific antibody (MM-111) was developed to target both ErbB2 and ErbB3. MM-111 was 
indicated to displace heregulin from ErbB3 and thereby prevents receptor phosphorylation, 
resulting in the inhibition of tumor growth. MM-111 in combination with trastuzumab is 
currently in a clinical trial to treat trastuzumab-resistant breast cancer (Arnett et al., 2011; 
National Cancer Institute, 2011, http://www.cancer.gov/clinicaltrials).  
Polyclonal or oligoclonal antibodies refer to the recombinant polycolonal or oligoclonal 
antibodies directed against the same or different targets. For example, the Rhesus D blood 
group antigen-specific polyclonal antibody rozrolimupab (Sym001; Symphogen A/S), which is 
a mixture of 25 unique recombinant monoclonal antibodies, is currently in Phase II clinical 
trials for the treatment of chronic and acute idiopathic thrombocytopenic purpura (Beck et al, 
2010; Swann, et al 2008;). Hopefully, in the near future we will see more optimized monoclonal 
antibodies entering the clinical trials to treat trastuzumab-resistant disease.  
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8.4 Antibody-drug conjugates (ADC)  
An important approach to delivering a lethal quantity of cytotoxic agent to the cancer cells is 
to select an antibody that specifically binds to a cancer-specific antigen that can mediate a 
rapid rate of endocytosis of antibody conjugate and accumulate them at a high 
concentration in cancer cells, thus resulting in cancer cell-specific killing while minimizing 
damage to normal cells (Chen at al., 2005; Senter, 2009). Antibody-drug conjugates are 
monoclonal antibody-based products that are covalently attached to the cytotoxic agent by 
chemical linkers (Alley et al., 2010). It is now a common strategy to develop monoclonal 
antibody-cytotoxic drug conjugates to improve the efficacy of both the monoclonal antibody 
and the cytotoxic agent for cancer indications (Chen at al, 2005; Senter, 2009). Antibody-drug 
conjugates consist of three different elements: the monoclonal antibody, linker, and 
cytotoxic agent. Three different classes of cytotoxic agents, including calicheamicin-based, 
maytansinoid-based, and auristatin-based cytotoxic agents, are commonly used as drugs to 
be conjugated to antibodies. Calicheamicin is a natural product and has been the subject of 
extensive research for drug delivery, due to its ability to bind to DNA in the minor groove, 
resulting in DNA cleavage. Maytansinoid derivatives and auristatin represent other classes 
of highly potent drugs that have been widely utilized for antibody-drug conjugate 
development. Both cytotoxic agents, maytansinoid derivatives and auristatin, act by binding 
to tubulin to mediate inhibition of tubulin polymerization (Chari, 2008; Doronina et al, 2006; 
Doronina et al. 2003). Traditionally, the antibody in an antibody-drug conjugate functions as 
a vehicle to carry drugs to the tumor site and drugs with high systemic toxicity are selected 
as payload in the antibody-drug conjugate. Gemtuzumab ozogamicin (Mylotarg), an anti-
CD33 antibody conjugated to calicheamicin, was granted marketing approval for the 
treatment of relapsed acute myeloid leukemia in 2000. It was withdrawn from the U.S. 
market in June 2010 when a clinical trial showed that the drug failed to demonstrate clinical 
benefit to the patients enrolled in clinical trials.  
Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that was generated by linking 
the maytansinoid derivative maytansin to trastuzumab via a thioether linker (Lewis Phillips 
et al., 2008). Testing of T-DM1 in a panel of HER2-positive trastuzumab-sensitive and 
trastuzumab-resistant cell lines indicated that T-DM1 was cytotoxic in both trastuzumab-
sensitive and trastuzumab-resistant breast cancer cell lines (Lewis Phillips et al. 2008). T-
DM1 also inhibited tumor growth and caused tumor regression in trastuzumab resistant 
animal xenograft models (Lewis Phillips et al. 2008). T-DM1 was reported to retain the 
mechanisms of action of trastuzumab and was also active against lapatinib-resistant cell 
lines and tumors (Junttila et al., 2010). A Phase I clinical trial testing of T-DM1 reported that 
T-DM1 was associated with clinical activity in HER2-positive patients who had progressed 
on trastuzumab–based therapy (Krop et al., 2010). A Phase II study recently reported that T-
DM1 had robust single-agent activity in metastatic breast cancer patients who had 
progressed on the previous HER2-directed therapy (Burris III et al., 2011). These clinical 
studies provide the evidence that the HER2 pathway remains a valid therapeutic target 
following disease progression on trastuzumab and suggest that antibody-drug conjugates 
are a novel and effective approach that can be used to treat trastuzumab-resistant disease.  
8.5 Development of novel therapeutic approaches: Mechanisms of resistance-based 
design of antibody drug conjugates 
Significant effort has been made to understand the mechanisms of resistance to 
trastuzumab. Many different small molecules, for example PI3 kinase inhibitors and c-Src 
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inhibitors have been shown to be able to revert trastuzumab-resistant phenotypes in 
preclinical settings (Junttila et al., 2009; Zhuang et al., 2010). Table 3 summarizes some of the 
novel proposed molecular targets involved in trastuzumab-resistance and small molecules 
that are able to override trastuzumab-resistant phenotypes based on the preclinical studies. 
 
Molecular target 
implicated in 
trastuzumab resistance 
Inhibitor for the target 
(preclinical studies) 
Reference for the preclinical 
studies 
Rac1 NSC23766 Dokmanovic et al., 2009 
EGFR Lapatinib 
Neratinib  
Nahta et al.,2007  
Burstein et al.,2010  
PI3K GDC-0941 
LY294002 
Wortmannin 
SF1126 
Junttila et al., 2009 
Clark et al., 2002  
Nagata et al., 2004 
Ozbay et al., 2010 
Akt Triciribine (API-2) Lu et al.,2007 
mTOR RAD001(everolimus) Lu et al.,2007  
PI3K/mTOR NVP-BEZ235 Serra et al., 2008 
PDK-1/Akt OSU-03012 Tseng et al., 2006 
HSP90 SNX-2112 
17-AAG 
Chandarlapaty et al., 2010 
Modi et al., 2007  
TGF-β1 LY2109761 Wang et al., 2008 
Src Dasatinib Zhuanget al., 2010  
Proteasome LLnL Lu et al., 2004 
Hyaluronan synthesis 4-MU 
(methylumbelliferon) 
Palyi-Krekk et al., 2007 
Fatty acid synthase C-75 Vazquez-Martin et al., 2007 
Table 3. Emerging molecular targets implicated in the trastuzumab-resistance and their 
respective inhibitors. 
TGF-β is a secreted ligand that binds to type I and type II TGF-β receptors and induces the 
secretion of HER family ligands, such as TGF-ǂ, amphiregulin, and heregulin. Secreted HER 
family ligands may enhance the association of p85 subunit of PI3K with HER3 and activate 
PI3K/Akt (Wang et al., 2008). Treatment with TGF-ǃ or expression of TGF-β type I receptor 
in HER2-overexpressing cells reduced their sensitivity to the HER2 antibody trastuzumab. 
Inhibition of TGF-β type I receptor by LY2109761, a TGF-β receptor type I and type II dual 
inhibitor, restored sensitivity to trastuzumab (Wang et al., 2008). Rac1 is a Ras-like small 
GTPase which is believed to be associated with breast cancer progression and metastasis 
(Sahai & Marshall, 2002). Inhibition of Rac1 activity by Rac1 specific inhibitor, NSC23766, 
resulted in the restoration of the trastuzumab-mediated HER2 endocytic degradation and 
inhibition of the cell growth in trastuzumab-resistant cells (Dokmanovic et al., 2009). It has 
been reported that the inhibition of c-Src activity by dasatinib partially restored trastuzumab 
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sensitivity in trastuzumab-resistant breast cancer cells (Zhuang et al., 2010). 4-MU inhibition 
of hyaluronan synthase enhanced trastuzumab-mediated growth inhibition in trastuzumab-
resistant JIMT-1 xenografts (Palyi-Krekk et al., 2007). Inhibition of fatty acid syntheses 
(FASN) re-sensitized the trastuzumab-resistant SKBR3 cells to trastuzumab-mediated cell 
death (Vazquez-Martin et al., 2007). 
Several other approaches were utilized to interfere with the molecular pathways associated 
with trastuzumab-resistance in the preclinical studies. It has been recently reported that the 
overexpression of FoxM1, an oncogenic transcription factor, confers resistance to the 
trastuzumab (Carr et al., 2010). Attenuation of FoxM1 expression either by small interfering 
RNA or by an alternate reading frame (ARF)-derived peptide inhibitor increased the 
sensitivity to trastuzumab (Carr et al., 2010). Damiano et al. report that a novel toll-like 
receptor 9 agonist, which is also referred as the immune modulatory oligonucleotide (IMO), 
exerts antiangiogenic effects by cooperating with anti-EGFR or anti-VEGF antobodies, 
(Damiano et al., 2009). It was also shown that IMO and trastuzumab exert a cooperative 
antiangiogenic effect on trastuzumab-resistant breast cancer xenografts and that combining 
IMO and trastuzumab may be a potential strategy for the treatment of trastuzumab-resistant 
breast cancers (Damiano et al., 2009). The Y-box binding protein-1 (YB-1) is an oncogenic 
transcription/translation factor mediating expression of growth promoting genes such as 
EGFR and HER2. YB-1 is activated by phosphorylation at Serine 102 residue, and a decoy 
cell permeable peptide (CPP) functions as interference peptide to prevent endogenous YB-1 
phosphorylation and activation. This results in the down-regulation of both HER-2 and 
EGFR transcript level and protein expression (Law et al., 2010). Interestingly, treatment with 
CPP has been reported to enhance sensitivity and overcome resistance to trastuzumab in 
cells expressing amplified HER-2, suggesting that CPP may be a novel approach for the 
treatment of trastuzumab-resistant breast cancers (Law et al., 2010).  
Even though there were multiple mechanisms of trastuzumab-resistance proposed from the 
preclinical studies, the question remains how the knowledge gained from these cellular and 
animal models can be translated into the next generation of monoclonal antibodies to 
overcome therapeutic resistance to trastuzumab. Based on literature and data from our 
laboratory (Dokmanovic et al., 2009), we propose a new approach by designing an antibody-
drug conjugate (ADC) based on mechanisms of trastuzumab resistance. In this ADC, 
trastuzumab is conjugated by a small molecule that has ability to inhibit the cellular target(s) 
that has been demonstrated to contribute to trastuzumab-resistance. This proposed strategy 
may increase the magnitude and duration of the response to trastuzumab treatment.  
9. Conclusions 
Treatment with trastuzumab significantly improves outcomes for women with HER2-
positive breast cancer. However, therapeutic resistance to trastuzumab poses a significant 
challenge in the treatment of human breast cancer. Pre-clinical studies conducted in the past 
few years have improved our understanding of molecular mechanisms contributing to the 
trastuzumab-resistance, and potential predictive biomarkers, such as the serum levels of 
extracellular cellular domain (ECD) of HER2, the status of p95HER2 and IGF-IR, and loss of 
PTEN, have been reported. However, no predictive markers are currently used in the clinic 
to differentiate HER2-positive breast cancers that would respond favorably to trastuzumab 
from trastuzumab-resistant disease. Validation of novel predictive biomarkers must be 
performed with clinical samples in the context of prospective clinical trial in which 
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prognostic or predictive questions can be answered (Hirsch & Wu, 2007; Murphy et al., 
2005). Resistance to monoclonal antibody therapeutics represents a common obstacle to the 
clinical efficacy for monoclonal antibody-based therapy. Understanding the molecular 
mechanisms of trastuzumab-resistance will lead to the discovery of new therapeutic targets, 
as well as more effective approaches. Innovative strategies to optimize antibody structures 
to develop next generation of monoclonal antibodies, such as antibody-drug conjugates, 
bispecific antibodies, and antibodies with either enhanced or silenced effector function, will 
also play a critical role in overcoming therapeutic resistance to monoclonal antibodies.  
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